Early-Stop trial tests new drug for Tough-to-Treat blood cancer
NCT ID NCT04486391
Summary
This study aimed to compare a new immunotherapy drug, tislelizumab, against standard chemotherapy for people with Hodgkin lymphoma that had returned or stopped responding to previous treatments. The goal was to see if the new drug could help patients live longer without their cancer getting worse. The trial was stopped very early, enrolling only 3 participants, so no clear results are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130021, China
-
Quanzhou First Affliated Hospital of Fujian Medical University
Quanzhou, Fujian, 362000, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.